CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers.

@article{Wallace1994CTLA4IgTA,
  title={CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers.},
  author={Philip M. Wallace and Joni S. Johnson and John Macmaster and Katherine A. Kennedy and P. Gladstone and Peter S. Linsley},
  journal={Transplantation},
  year={1994},
  volume={58 5},
  pages={602-10}
}
Graft-versus-host disease (GVHD), a pathological condition associated with BMT, results from activation of donor T lymphocytes by host tissues. CD28 and CTLA-4 are structurally related T cell receptors for members of the B7 (CD80) gene family, which transmit important costimulatory signals for T cell activation in vitro and in vivo. Here we have investigated the effects of CTLA4Ig, a soluble form of CTLA-4, on lethal GVHD in a murine model. Lethal GVHD was induced by transfer of parent C57BL/6… CONTINUE READING